Oxprenolol, a new beta-receptor blocking drug with intrinsic sympathomsnetic activity, was used to treat 63 episodes of cardiac arrhythmia occuring in 43 patients with acute myocardial infarction or myocardial ischaemia. The drug was most effective in abolishing ventricular ectopic beats and supraventricular tachycardia. The best method of administration was by continuous intravenous infusion and the most satisfactory bolus dose was 6 mg. The main side effect was hypotension, which occurred in 59% of episodes of arrhythmia that had responded previously to intravenous administration. Oxprenolol was often effective in lignocaine-resistant arrhythmia. The two main advantages of oxprenolol over propranolol are the reduced likelihood of adversely affecting myocardial function and the diminished tendency to produce bronchospasm.
Introduction
Since the introduction of beta-adrenergic blocking drugs in cardiac arrhythmias by Stock and Dale in 1963 these drugs have been used extensively to treat a variety of arrhythmias associated both with acute myocardial infarction and with chronic heart disease (Harrison et al., 1965; Bath, 1966; Epstein and Braunwald, 1966; Frieden et al., 1967; Irons et al., 1967; Theilen and Wilson, 1968) . There are, however, two main disadvantages associated with the use of these drugs: firstly, a deleterious effect on myocardial function (Chamberlain, 1966; Stephen, 1966) ; and, secondly, an adverse effect on the bronchial musculature leading to bronchospasm (McNeill, 1964; Sandler and Clayton, 1970) . Oxprenolol is a new beta-adrenergic blocking agent which is equipotent with propranolol in its negative chronotropic action, but is claimed to produce significantly less depression of myocardial contractility (Grandjean and Rivier, 1968) . Preliminary observations have suggested that the antiarrhythmic action of oxprenolol is as effective as that of propranolol (Waal, 1968) , but the assessment was based on oral therapy mainly in outpatients with arrhythmias associated with chronic heart disease. In view of the potential value of oxprenolol in treating acute Coronary Care Unit, St. Helen Hospital, Bamsley G. SANDLER, M.D., M.R.C.P., Consultant Physician A. C. PISTEVOS, M.D., Senior House Officer arrhythmias after myocardial infarction, it was decided to investigate the use of parenteral therapy with oxprenolol in this situation.
Patients and Methods Forty-three patients aged 39 to 74 years were studied after admission to the coronary care unit. Thirty-four had typical QS and/or sequential S-T changes ip the electrocardiogram associated with raised serum enzymes (aspartate aminotransferase and lactate dehydrogenase), confirming acute myocardial infarction. This was anterior in 24, inferior in eight, and high lateral in two. Three patients had classical ischaemic pain, with left bundle-branch block on the electrocardiogram in one and raised serum enzymes without E.C.G. changes in the other two. Five patients had ischaemic cardiac pain but no E.C.G. or enzyme changes, and one patient was admitted for a pulmonary embolus. Some of the patients had more than one episode of arrhythmia, so that the total number of attacks of arrhythmia treated was 63.
All patients were monitored continuously on an oscilloscope, and tracngs were obtainable on a direct-writing recorder linked with the oscilloscope. Electrocardiographic records were taken before and at frequent intervals (usually every 30 seconds) after administration of oxprenolol. Particular attention was also paid to the effects of the drug on the blood pressure, and other side effects were also carefully noted.
Patients with bronchial asthma, heart failure, atrioventricular block, and bradycardia were excluded from the trial.
The acute effects of oxprenolol on the arrhythmias were studied by single intravenous bolus injections of the drug in various doses and also by means of cQntinuous intravenous infusion. The bolus injection was given initially in a dose of 2 mg, and if this was not effective within 10 minutes a further injection of 4 mg was given. If no effect was obtained after a further 10 minutes a final bolus of 6 mg was given provided that no significant hypotensive or other adverse side effects appeared. The continuous intravenous infusion was given by electrically driven syringe pump, using 30 mg of oxprenolol mixed with 30 ml of sterile water B P., and the infusion rate was adjusted to deliver oxprenolol in a dose of 0.25 mg/minute. The infusion was continued until suppression of the arrhythmia or until the total dose was delivered over a period of two hours. In addition to the intravenous study, the effect of oral oxprenolol in a dose of 20 to 40 mg six-hourly was assessed in a number of patients as a prophylactic measure.
The types of arrhythmia studied included supraventricular tachycardia (the atrial rate exceeding 120/minute), supraventricular ectopic beats (atrial and nodal) occurring more frequently than once every 10 normal beats, atrial fibrillation, ventricular ectopic beats (unifocal exceeding 1 in 10 normal beats, multifocal of any frequency, and especially R-on-T), and ventriciLar tachycardia. Oral oxprenolol was given to patients who had previously responded successfully to intravenous administration but had developed a recurrence of a similar arrhythmia within several hours.
Results
Supraventricular Tachycardia.-The effectiveness of the control achieved by oxprenolol, based on the final heart rate, has been related to the initial heart rate ( Table I) . Thirteen out of 27 episodes can be regarded as attaining good control with oxprenolol, the heart rate dropping to below 100/minute. Less satisfactory control was obtained in a further seven episodes in which the average fall in heart rate was 24/minute and the final rate achievpd was 100-109/minute. Though the average fall in heart rate in the remainng seven episodes was 33/minute, the final rate was unsatisfactory, over 110/minute.
The results show that successful control with oxprenolol seems to be inversely related to the rapidity of the initial heart rate. Fall in blood pressure after oxprenolol related to fall in heart rate in patients with supraventricular tachycardia.
of 20 mg four times a day, except in one patient whose dosage was 40 mg four times a day-was tried in 21 patients in whom previous intravenous administration had been effective in suppressing the recurrent arrhythmia. A favourable response was found in both supraventricular and ventricular arrhythmias with a total of 74% of the episodes suppressed (Table V) .
Comparison with Lignocaine.-The effectiveness of oxprenolol after lignocaine has failed, and vice versa, is shown in Table VI . In supraventricular tachycardia the attack was regarded as abolished if the heart rate fell to below 100/minute, while a final heart rate of 100-120/minute was listed as "less severe." Similarly, in this table the response of ectopic beats to treatment was based on their complete abolition or reduction in frequency without abolition ("less severe"). Oxprenolol either abolished or improved the arrhythmia in 9 out of 13 episodes (69%) in which lignocaine had previously been ineffective, including both supraventricular tachycardia and ventricular ectopic beats. On the other hand, lignocaine was even more effective when oxprenolol had failed, 80% of episodes responding to treatment with lignocaine. The main superiority of lignocaine over oxprenolol was in treating ventricular ectopic beats, where seven out of eight oxprenolol-resistant episodes responded to lignocaine. Discussion Though the mechanism of action of beta-blocking drugs in cardiac arrhythmia has been the subject of controversy, probably both the beta-blocking activity (Williams, 1966) and the quinidine-like suppressive action on the myocardial cell membrane (Sekiya and Williams, 1964; Lucchesi, 1965 ) play a part. However, the negative inotropic action of this group of drugs, exemplified most extensively by propranolol, may adversely affect cardiac function, leading on occasions to serious heart failure (Stock, 1966; Szekely et al., 1966; Harrison, 1969) . This is particularly relevant in the early stages of acute myocardial infarction where the incidence of left ventricular failure may be over 60% (Lown, 1968) . Oxprenolol has been found to be a potent beta-receptor blocker both experimentally (Bender, 1968) and in man (Grandjean and Rivier, 1968), but it differs from propranolol in producing significantly less depression of myocardial contractility in therapeutic doses (Grandjean and Rivier, 1968; Nayler et al., 1969) . This is probably due to its intrinsic sympathomimetic activity (Brunner et al., 1968 ), a property not possessed by propranolol. The present study has confirmed the effectiveness of oxprenolol in treating ventricular ectopic beats, over 70% of the episodes being abolished by the drug; in addition it was effective in all three cases of idioventricular rhythm in which it was tried. A similarly satisfactory response was also obtained with supraventricular tachycardia, almost half the episodes being abolished and another 25% improved with a fall of atrial rate below 110/minute. The response to oxprenolol was more disappointing with supraventricular ectopic beats, but this may be attributable to a less pronounced influence of catecholamine release in producing these arrhythmias in the early stages of myocardial infarction compared with ventricular ectopic beats, where catecholamine release is much greater (Jewitt et al., 1969 .
The most significant side effect of oxprenolol was its hypotensive effect, which occurred in varying degree in over half of the patients investigated, the fall affecting both systolic and diastolic pressure. Though part of this hypotensive action may be attributable to the reduction in heart rate after oxprenolol, the relationship is not a consistent one, suggesting the possibility that the negative inotropic effect of the drug may also be an important factor in causing the fall in blood pressure. Similar hypotensive effects of intravenous oxprenolol have been described in normotensive subjects by Wilson et al. (1968) The only other side effect encountered was nausea, which occurred in only one or two patients. No patient showed any evidence of cardiac decompensation as a result of oxprenolol administration. Oxprenolol, therefore, would appear to offer an advantage over propranolol in having less tendency to produce adverse effects on myocardial function. Whereas both propranolol and oxprenolol reduce the heart rate at rest and after exercise, oxprenolol leads to a smaller reduction of cardiac output than propranolol, since the resultant bradycardia with oxprenolol is compensated by a greater increase in stroke volume (Grandjean and Rivier, 1968) . The other potential advantage is the less pronounced effect on bronchial muscle, though this aspect was not investigated in the present study. Beumer et al. (1968, 1969) 
